We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. “Since taking over as the Acting CEO, we have been able to attract interest from unrelated third parties that may enable us to secure value from the intellectual property we have built and which gave rise to several new strategic opportunities that could enhance enterprise value for all of our stakeholders. Institutional InvestorsIn-Site Communications, Inc.Lisa Wilson, President MZ North America Institutional Investors E: lwilson@insitecony.com Lisa Wilson, President E: lwilson@insitecony.com No peer-reviewed data is available yet for the Orion system. E: greg.falesnik@mzgroup.us. Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced today that the Company has taken significant steps to reduce overhead and conserve liquidity as it continues operations while assessing strategic options. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. 06.27.19. Source: Second Sight Medical Products, Inc. Second Sight Medical Products Provides Business Update, https://www.businesswire.com/news/home/20200428005410/en/. T: 949-385-6449 Going through the last 3-months fiscal report unveiled on the 3/30/2020, it has been observed that the corporation posted -$0.57 earnings per share (EPS) during the time that was less the consensus figure (set at … Source: Second Sight Medical Products . T: 949-385-6449 Time (ET) Business Wire. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. All statements that address operating performance or events or developments that Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, our refinement of strategy, including the outcome of our announced downgrading of operations, our attempts to secure additional financing, our exploring possible business alternatives, or that are not otherwise historical facts, are forward-looking statements. EYES | Complete Second Sight Medical Products Inc. stock news by MarketWatch. Genetic Technologies leads healthcare gainers; Pulmatrix and Moleculin Biotech among losers. or This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the “safe harbor” created by those sections. T: 949-385-6449 A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company remains encouraged by the positive interim results from the six subjects at the Ronald Reagan UCLA in Los Angeles and the Baylor College of Medicine in Houston who have been implanted with the Orion® Visual Cortical Prosthesis System, and the potential to advance the technology into larger clinical studies to treat profound blindness arising from nearly all forms of preventable blindness. E: lwilson@insitecony.com Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements as a result of various factors, including those risks and uncertainties described in or implied by the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report on Form 10-K, filed on March 19, 2020 and our other reports filed from time to time with the Securities and Exchange Commission. Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual pro No assurances can be given that any of these initiatives will occur. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. Individual Investors While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Headline. 10.01.19. Laura Nobles or Helen Shik T: 212-452-2793 View real-time stock prices and stock quotes for a full financial overview. 28, 2020-- Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements as a result of various factors, including those risks and uncertainties described in or implied by the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report on Form 10-K, filed on March 19, 2020 and our other reports filed from time to time with the Securities and Exchange Commission. Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Yeast Infection With Blood Tinged Discharge, Introduction Of Pharmaceutical Microbiology, Junior Software Developer Positions, Long War Of The Chosen 31, Winsor And Newton Oil Paint Bulk, Advantages Of Salt Water Energy,